Scholar Rock Holding Surges to 456th in Market Rankings with 176 Million in Trading Volume

On June 18, 2025, Scholar Rock Holding (SRRK) saw a significant surge in trading volume, with a total turnover of 176 million, marking a 698.56% increase from the previous day. This substantial rise placed SRRK at the 456th position in the daily stock market rankings, reflecting a notable increase in investor interest. The stock price of SRRK rose by 16.89%.

Scholar Rock Holding Corp reported encouraging results from the Phase 2 EMBRAZE study, which evaluated the combination of apitegromab and tirzepatide. The trial demonstrated that patients receiving apitegromab with tirzepatide over a 24-week period experienced a 54.9% preservation of lean mass, gaining an additional 4.2 pounds of lean mass compared to those receiving tirzepatide alone. This finding underscores the potential of apitegromab in enhancing the efficacy of tirzepatide by mitigating lean mass loss, which accounted for 30% of total weight loss when tirzepatide was used alone. The study's outcomes highlight the therapeutic benefits of apitegromab in preserving lean mass, which could have significant implications for future clinical applications.